LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
Delayed Nyse  -  04:00 2022-07-01 pm EDT
240.94 USD   +2.81%
06/28Laboratory Corp of America Plans Lab Expansion in Japan
MT
06/28Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration
BU
06/28Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
241.31(c) 235.96(c) 240(c) 234.36(c) 240.94(c) Last
613 054 608 347 744 290 867 103 436 032 Volume
-0.52% -2.22% +1.71% -2.35% +2.81% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 15 300 M - -
Net income 2022 1 551 M - -
Net Debt 2022 3 677 M - -
P/E ratio 2022 14,3x
Yield 2022 0,45%
Sales 2023 15 431 M - -
Net income 2023 1 414 M - -
Net Debt 2023 3 731 M - -
P/E ratio 2023 15,5x
Yield 2023 0,58%
Capitalization 22 335 M 22 335 M -
EV / Sales 2022 1,70x
EV / Sales 2023 1,69x
Nbr of Employees 71 725
Free-Float 99,7%
More Financials
Company
Laboratory Corporation of America Holdings is the No. 2 clinical laboratory in the United States. Net sales (including intragroup) break down by activity as follows: - supply of testing services (59.5%): routine testing, patient diagnosis, disease monitoring and treatment, and other services; - supply of genomic and esoteric testing services (40.5%). Net sales are distributed geographically as follows : the... 
More about the company
Ratings of Laboratory Corporation of America Holdings
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
06/28Laboratory Corp of America Plans Lab Expansion in Japan
MT
06/28Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration
BU
06/28Labcorp Plans Laboratory Expansion in Japan Through BML Collaboration
CI
06/27Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for W..
AQ
06/24 Tigerlily Foundation and Labcorp Collaborate to Increase Clinical Trial Diversity for ..
BU
06/24Labcorp and Tigerlily Foundation Announce New Collaboration to Increase Clinical Trial ..
CI
06/24LABORATORY CORPORATION OF AMERICA HO : LH) added to Russell 1000 Dynamic Index
CI
06/21Labcorp Teams With HealthVerity to Expand Clinical Trial, Drug Development Capabilities
MT
06/21Labcorp Enhances Clinical Trial and Drug Development Capabilities Through Real World Da..
BU
06/08Florida Supreme Court Finds Workers' Comp Law Does Not Bar Improper Debt Collections Ac..
AQ
06/03Labcorp to Provide Testing Device for Eli Lilly-Sponsored Lung Cancer Testing Program
MT
06/02Labcorp Expands Access to Comprehensive Genomic Testing Through New Lung Cancer Program
BU
05/27Performance Marketing Group XLMedia Names New CEO
MT
05/25Morgan Stanley Adjusts Price Target for Laboratory Corp of America Holdings to $300 Fro..
MT
05/24TRANSCRIPT : Laboratory Corporation of America Holdings Presents at UBS Global Healthcare ..
CI
More news
News in other languages on LABORATORY CORPORATION OF AMERICA HOLDINGS
06/28Laboratory Corp of America prévoit l'expansion de ses laboratoires au Japon
06/28Labcorp prévoit l'expansion de ses laboratoires au Japon grâce à une collaboration avec..
06/24Labcorp et la Tigerlily Foundation annoncent une nouvelle collaboration visant à accroî..
05/18Labcorp lance un nouveau test pour les personnes atteintes d'un cancer de la peau
05/18Labcorp reçoit une autorisation d'utilisation d'urgence pour le premier kit de prélèvem..
More news
Analyst Recommendations on LABORATORY CORPORATION OF AMERICA HOLDINGS
More recommendations
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 240,94 $
Average target price 302,71 $
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Adam H. Schechter Chairman, President & Chief Executive Officer
Glenn Andrew Eisenberg Chief Financial Officer & Executive Vice President
Lance V. Berberian Chief Information & Technology Officer & EVP
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP
Sector and Competitors